Healthcare / Drug Manufacturers - Specialty & GenericNSE
$6.42
+0.27 (+4.19%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-62.8M · quality 45.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$532M
P/E
N/A
•EV/EBITDA
N/A
•ROE
90.9%
↑Gross Margin
45.3%
↓Debt/Equity
-10.70
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-21.1%
FCF CAGR
—
FCF margin
-5.4%
FCF / Net income
0.20x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.16B · net income $-319.6M · FCF $-62.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.16B | $1.16B | $1.49B | $1.87B | $2.37B |
| Net Income | $-319.6M | $-319.6M | $-454.5M | $-3.29B | $-676.5M |
| EBITDA | $-98.9M | $-98.9M | $-246.7M | $-1.87B | $-80.1M |
| EPS | -3.85 | -3.85 | -5.48 | -39.62 | -8.16 |
| Gross Margin | 45.3% | 45.3% | 48.0% | -49.6% | 30.3% |
| Operating Margin | -24.9% | -24.9% | -13.8% | -109.9% | -11.0% |
| Net Margin | -27.5% | -27.5% | -30.5% | -175.6% | -28.6% |
| Balance Sheet | |||||
| Debt/Equity | -10.70 | -10.70 | -69.36 | 9.67 | 0.99 |
| Cash Flow | |||||
| Free Cash Flow | $-62.8M | $-62.8M | $-260.3M | $303.5M | $111.3M |
| Returns | |||||
| ROE | 90.9% | 90.9% | 832.2% | -833.4% | -18.6% |
| Valuation | |||||
| P/B | — | — | — | 1.49 | 0.40 |
| Growth & Yield | |||||
| Revenue Growth | -22.0% | -22.0% | -20.3% | -20.9% | — |
| EPS Growth | 29.7% | 29.7% | 86.2% | -385.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+35.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-5.48 → -3.85
Residual
+35.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.